Preimplantation Genetic Testing Market by Technology, Offering, Procedure Type, Application, End User

Description

List of Tables

[192 Pages Report] The Preimplantation Genetic Testing Market size was estimated at USD 728.40 million in 2023 and expected to reach USD 829.06 million in 2024, at a CAGR 14.56% to reach USD 1,886.28 million by 2030.

Preimplantation genetic testing (PGT) refers to technologies used to detect chromosomal abnormalities affecting the embryos before implantation. PGT is a crucial service that allows for early detection of genetic abnormalities in embryos before implantation during in-vitro fertilization (IVF) procedures, significantly reducing the risk of passing on inheritable diseases to offspring and improving IVF success rates. The primary application areas for PGT include identifying monogenic disorders, chromosomal abnormalities, mitochondrial diseases, and human leukocyte antigen (HLA) matching for potential siblings. The rising infertility rates due to lifestyle changes and delayed parenthood choices among couples have necessitated the development of PGT technologies. Government initiatives promoting IVF treatments create numerous expansion opportunities. However, high costs associated with IVF treatments and PGT procedures can be a major deterrent to potential end-users. Ethical concerns surrounding PGT and limited insurance coverage for IVF treatments hinder the adoption of PGT services. Major biotechnology companies are rapidly expanding efforts to combat ethical and regulatory challenges and creating technologies that take moral and ethical issues under consideration. New approaches such as next-generation sequencing (NGS) and non-invasive preimplantation testing are emerging technologies that offer significant potential for the growth of the technology.

KEY MARKET STATISTICS
Base Year [2023]	USD 728.40 million
Estimated Year [2024]	USD 829.06 million
Forecast Year [2030]	USD 1,886.28 million
CAGR (%)	14.56%

Technology: Advancements in next-generation sequencing to detect chromosomal abnormalities and single-gene disorders

Comparative genomic hybridization (CGH) is adopted for detecting chromosomal imbalances by comparing the DNA of two samples. It can detect chromosomal abnormalities in embryos before implantation and help select healthy embryos for IVF. Fluorescence in situ hybridization (FISH) is a technique that uses fluorescent probes to visualize and map specific DNA sequences on chromosomes within cells. It can detect numerical chromosomal abnormalities, including aneuploidy or translocations. Next-generation sequencing (NGS) is a robust tool for preimplantation genetic testing owing to its ability to sequence large amounts of DNA quickly and accurately. Polymerase chain reaction (PCR) is a widely used molecular biology technique that amplifies specific DNA sequences for analysis and can detect monogenic diseases. Single-nucleotide polymorphism (SNP) evaluates variations at the single-nucleotide level within the genome and is used to identify carriers of inherited diseases or assess the risk of multifactorial disorders, including cancer.

Offering: Utilization of diverse offerings to optimize process conditions and derive accurate results

Instruments play a critical role in the PGT process as they enable accurate and efficient genetic screening of embryos. Key instruments include next-generation sequencers (NGS), quantitative PCR (qPCR) systems, and fluorescence in situ hybridization (FISH) analyzers. NGS offers high-throughput sequencing capabilities and a broader detection range, making it suitable for detecting single-gene disorders and chromosomal abnormalities. Reagents and consumables used for PGT consist of various kits, probes, buffers, enzymes, and solutions necessary for genetic testing procedures. Probes are vital in detecting specific chromosomal aberrations, and buffers provide appropriate conditions for optimal amplification conditions. Software and services are essential components of PGT, as they ensure reliable data management, analysis, interpretation, and reporting for genetic testing results. Need-based preferences revolve around user-friendly interfaces, accurate algorithms for variant detection, comprehensive databases for variant annotation, and secure data storage options.

Procedure: Increasing deployment of preimplantation genetic diagnosis (PGD) procedures to reduce the risk of genetic disorders

Preimplantation genetic diagnosis (PGD) is a specialized procedure that allows the identification of genetic mutations or chromosomal abnormalities in embryos diagnosed before implantation and pregnancy. The primary goal of PGD is to reduce the risk of developing specific genetic disorders such as cystic fibrosis, Huntington's disease, and muscular dystrophy. Preimplantation genetic screening (PGS), referred to as preimplantation genetic testing for aneuploidies (PGT-A), detects chromosomal aneuploidies or imbalances in embryos before implantation. PGS aims to improve the chances of successful pregnancies by identifying embryos with the correct number of chromosomes, reducing the risk of miscarriage, stillbirth, or having a child affected by Down syndrome or other chromosomal abnormalities.

Application: Wide use of preimplantation genetic testing for aneuploidy disorder

Aneuploidy is a disorder in which an abnormal number of chromosomes in a cell leads to genetic disorders, including Down syndrome, Edwards syndrome, and Patau syndrome. Preimplantation of genetic testing for aneuploidy (PGT-A) identifies embryos with chromosomal abnormalities before implantation, increasing the chances of a successful pregnancy outcome. Gender identification through preimplantation genetic testing allows couples to choose the gender of their child for family balancing or to avoid sex-linked disorders. Human leukocyte antigen (HLA) typing matches tissue types between donor and recipient for stem cell or organ transplantation procedures. Preimplantation HLA typing identifies embryos with compatible tissue types, potentially facilitating successful transplants in siblings with blood disorders or immune system deficiencies. Structural chromosomal abnormalities involve alterations in chromosome structure, including deletions, duplications, and rearrangements. In addition, X-linked diseases are caused by mutations in genes on the X chromosome, affecting males more severely than females.

End User: Increasing adoption of PGT in healthcare research organizations for accurate diagnosis and effective treatments

Preimplantation genetics testing is widely used in various healthcare facilities, providing successful outcomes in clinical research. Contract research and manufacturing organizations (CRMOs) are primary organizations that play a crucial role in developing, manufacturing, and commercializing preimplantation genetic testing products. These organizations prefer outsourcing their services to ensure quality control, compliance with regulatory standards, and cost efficiency while focusing on their core competencies. Similarly, cryobanks are institutions that store biological samples such as sperm, eggs, and embryos at extremely low temperatures for future use. Preimplantation genetic testing is crucial for cryobanks to ensure the genetic viability of stored samples before implantation procedures like IVF or ICSI. Hospitals, diagnostic labs, and service providers contribute to patient care through accurate diagnosis and effective treatments using preimplantation genetic testing technologies. Research laboratories and academic institutes play a vital role in driving innovation and advancements in preimplantation genetic testing through cutting-edge research, technological developments, and interdisciplinary collaborations. These institutions focus on developing novel techniques like next-generation sequencing (NGS) to enhance the accuracy of preimplantation genetic testing methods.

Regional Insights

The Americas exhibit a high need for preimplantation genetic testing (PGT) owing to rising infertility rates caused by lifestyle changes and increasing awareness regarding genetic testing. Well-established healthcare infrastructure facilities and favorable reimbursement policies have made PGT services more accessible to couples seeking infertility treatments in the Americas. Companies in the region have strong R&D capabilities and government support that drive innovation in the field. Asia is emerging as a big and opportunistic market for PGT owing to improved provision of advanced fertility techniques such as IVF with PGT services and growing medical tourism, attracting international patients seeking cost-effective treatment options. Europe contributes significantly to the global PGT market due to factors such as increased government funding for healthcare research and widespread adoption of IVF procedures across various European countries. Moreover, stringent regulatory frameworks surrounding genetic testing ensure quality control and ethical considerations when implementing PGT services. Key players within this region contribute significantly to technological advancements in preimplantation genetic testing practices.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Preimplantation Genetic Testing Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Preimplantation Genetic Testing Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Preimplantation Genetic Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Bioarray S.L., EUROPE IVF International s.r.o., F. Hoffmann-La Roche AG, Genea Limited, GENETiKS, Illumina, Inc., Invicta Genetics, Invitae Corporation, Juno Genetics, US Inc., Laboratory Corporation of America Holdings, MedGenome Labs Ltd., Merck KGaA, Natera, Inc., NextGen Genetics Holdings, LLC, Ovation Fertility, PacGenomics, PerkinElmer, Inc., Progyny, Inc., Qiagen N.V., Quest Diagnostics Incorporated, Reproductive Genetic Innovations, LLC, SEQUENCE46, LLC, Sysmex Corporation, Takara Bio Inc., The Cooper Companies Inc., Thermo Fisher Scientific Inc., Vitrolife Sweden AB, and Yikon Genomics (Shanghai) Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Preimplantation Genetic Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

Technology
- Comparative Genomic Hybridization
- Fluorescence in-Situ Hybridization
- Next-Generation Sequencing
- Polymerase Chain Reaction
- Single-Nucleotide Polymorphism

Offering
- Instruments
- Reagents & Consumables
- Software & Services

Procedure Type
- Preimplantation Genetic Diagnosis
- Preimplantation Genetic Screening

Application
- Aneuploidy
- Gender Identification
- HLA Typing
- Single Gene Disorders
- Structural Chromosomal Abnormalities
  - Deletions
  - Duplications
  - Inversions
  - Translocations

X-Linked Disorders

End User
- Contract Research & Manufacturing Organizations
- Cryobanks
- Hospitals, Diagnostic Labs, & Service Providers
- Research Laboratories & Academic Institutes

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Preimplantation Genetic Testing Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Preimplantation Genetic Testing Market?

3. What are the technology trends and regulatory frameworks in the Preimplantation Genetic Testing Market?

4. What is the market share of the leading vendors in the Preimplantation Genetic Testing Market?

5. Which modes and strategic moves are suitable for entering the Preimplantation Genetic Testing Market?

Product Code: MRR-030EE48515DA

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Significant incidences of fetal abnormalities and need for healthy and successful embryo implantation
  - 5.1.1.2. Increase in the rate of infertility and the rising number of fertility clinics worldwide
  - 5.1.1.3. Growing early diagnostic approaches coupled with increasing government support to treat genetic diseases
- 5.1.2. Restraints
  - 5.1.2.1. Limitation and risks associated with PGT
- 5.1.3. Opportunities
  - 5.1.3.1. Technological advancement in the field of preimplantation genetic analysis
  - 5.1.3.2. Emerging startup ecosystem and investments in the field of preimplantation genetic testing
- 5.1.4. Challenges
  - 5.1.4.1. Ethical constraints and Misuse of PGT
5.2. Market Segmentation Analysis
- 5.2.1. Technology: Advancements in next-generation sequencing to detect chromosomal abnormalities and single-gene disorders
- 5.2.2. Offering: Utilization of diverse offerings to optimize process conditions and derive accurate results
- 5.2.3. Procedure: Increasing deployment of preimplantation genetic diagnosis (PGD) procedures to reduce the risk of genetic disorders
- 5.2.4. Application: Wide use of preimplantation genetic testing for aneuploidy disorder
- 5.2.5. End User: Increasing adoption of PGT in healthcare research organizations for accurate diagnosis and effective treatments
5.3. Market Trend Analysis
- 5.3.1. Presence of established companies and startups launching innovative preimplantation genetic solutions across the Americas
- 5.3.2. Supportive Government initiatives and the increasing infertility rate emphasized preimplantation genetic testing adoption in APAC
- 5.3.3. Rising adoption of preimplantation genetic testing for IVF across Europe and potential of global player expansion in Middle East & Africa
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework Analysis

6. Preimplantation Genetic Testing Market, by Technology

6.1. Introduction
6.2. Comparative Genomic Hybridization
6.3. Fluorescence in-Situ Hybridization
6.4. Next-Generation Sequencing
6.5. Polymerase Chain Reaction
6.6. Single-Nucleotide Polymorphism

7. Preimplantation Genetic Testing Market, by Offering

7.1. Introduction
7.2. Instruments
7.3. Reagents & Consumables
7.4. Software & Services

8. Preimplantation Genetic Testing Market, by Procedure Type

8.1. Introduction
8.2. Preimplantation Genetic Diagnosis
8.3. Preimplantation Genetic Screening

9. Preimplantation Genetic Testing Market, by Application

9.1. Introduction
9.2. Aneuploidy
9.3. Gender Identification
9.4. HLA Typing
9.5. Single Gene Disorders
9.6. Structural Chromosomal Abnormalities
9.7. X-Linked Disorders

10. Preimplantation Genetic Testing Market, by End User

10.1. Introduction
10.2. Contract Research & Manufacturing Organizations
10.3. Cryobanks
10.4. Hospitals, Diagnostic Labs, & Service Providers
10.5. Research Laboratories & Academic Institutes

11. Americas Preimplantation Genetic Testing Market

11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific Preimplantation Genetic Testing Market

12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa Preimplantation Genetic Testing Market

13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape

14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
- 14.3.1. Thermo Fisher Unveils Ion ReproSeq PGT-A Kit and Ion AmpliSeq Polyploidy Kit
- 14.3.2. Kindbody Brings Genetic Testing In-House with the Launch of Kindlabs
- 14.3.3. Medicover Genetics and Fimlab Laboratories Announce Partnership to Provide Genetic Testing Services in Finland
- 14.3.4. U.S. Fertility and Ovation Combine to Create IVF Services Powerhouse, Increasing Access to Fertility Services
- 14.3.5. Eurofins Genoma Announces Launch of niPGT-A, a Non-Invasive, Embryo Biopsy Free, Preimplantation Genetic Aneuploidy Screening
- 14.3.6. GenEmbryomics Introduces the Most Complete IVF Genetic Test Ever Made Available
- 14.3.7. Singaporeans Undergoing IVF to Get New Funding For Some Types of Preimplantation Genetic Testing
- 14.3.8. Australia's Fertilis Raised USD 2 Million to Automate IVF Embryo Culturing

15. Competitive Portfolio

15.1. Key Company Profiles
15.2. Key Product Portfolio